Glucagen Hypokit (Glucagon)

Glucagen Hypokit is a glucagon‑containing injectable product marketed in the European Union. The preparation contains the hormone glucagon as its active ingredient; the specific strength and dosage form are not disclosed in the summary. It is supplied for intramuscular, intravenous, or subcutaneous administration and is available by prescription only. It is intended for emergency treatment of severe hypoglycemia in patients with diabetes. The kit includes a ready‑to‑use syringe and glucagon vial.

Glucagen Hypokit is indicated for the rapid reversal of severe hypoglycemia when oral carbohydrate intake is not possible or ineffective.

- Administration to adults and children experiencing insulin‑induced hypoglycemia unresponsive to oral glucose. - Emergency treatment for hypoglycemic episodes in patients with type 1 or type 2 diabetes. - Use when a rapid increase in blood glucose is required to prevent loss of consciousness. - Applicable in clinical settings such as hospitals, ambulances, or home care during diabetic emergencies. - Suitable for patients who are unable to swallow or have impaired gastric absorption.

Glucagen Hypokit may cause transient physiological responses related to its glucose‑raising action.

Common: - Nausea or vomiting - Flushing or warmth at the injection site - Transient headache - Mild abdominal discomfort

Serious: - Allergic reaction including rash, itching, or swelling - Severe hypotension or cardiovascular collapse (rare) - Pancreatitis (very rare)

Before using Glucagen Hypokit, healthcare providers should consider several precautionary factors to ensure safe administration.

- Confirm diagnosis of severe hypoglycemia and assess the need for injectable glucagon. - Avoid use in patients with known hypersensitivity to glucagon or any kit components. - Monitor blood glucose levels after administration to verify therapeutic response. - Exercise caution in patients with pheochromocytoma, adrenal insufficiency, or recent myocardial infarction. - Do not reuse the syringe; discard all components after a single use. - Pregnancy and lactation status should be evaluated, as safety data are limited. - Store the product according to manufacturer instructions, protecting it from extreme temperatures.

Glucagen Hypokit can interact with other medications or conditions that affect glucose metabolism or cardiovascular stability.

Avoid: - Concurrent use of beta‑blockers that may mask typical glucagon‑induced symptoms. - Co‑administration with insulin analogs in excess, which could exacerbate hypoglycemia after glucagon effect wanes.

Use with caution: - Patients receiving oral contraceptives or hormone therapy, as glucagon may alter hormone levels. - Individuals on anticoagulants, because intramuscular injection could increase bleeding risk. - Use in patients with severe renal or hepatic impairment, monitoring for prolonged effects.